{"id":59138,"date":"2024-02-28T05:43:27","date_gmt":"2024-02-28T05:43:27","guid":{"rendered":"https:\/\/medsname.com\/risdone-mt\/"},"modified":"2026-04-30T10:24:03","modified_gmt":"2026-04-30T10:24:03","slug":"risdone-mt","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/risdone-mt\/","title":{"rendered":"Risdone MT"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 R\u0103spuns rapid<\/h3>\n

Risdone MT (Risperidone 0.5 mg ODT) is an atypical antipsychotic for schizophrenia, bipolar mania, irritability in autism (paediatric and adolescent), and short-term aggression in dementia. Highest prolactin elevation of any atypical \u2014 relevant for fertility, menstrual function, and bone density.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Risdone MT at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a> \u2014 perioad\u0103 de livrare de 20 de zile lucr\u0103toare sau retrimitem f\u0103r\u0103 costuri suplimentare \u2014 \u0219i se calific\u0103 pentru programul nostru de loialitate pentru clien\u021bi<\/a>. Livr\u0103rile sunt disponibile \u00een majoritatea destina\u021biilor la nivel mondial.<\/p>\n

What Risdone MT is and how it works<\/h2>\n

Risdone MT is a risperidone orodispersible tablet supplied by Sun Pharma. Available strengths: 0.5 mg ODT<\/strong>. Risperidone is a strong D2 and 5-HT2A antagonist with \u03b11-adrenergic and H1 antihistamine activity, but minimal anticholinergic effect. The strong D2 blockade explains both the strong antipsychotic effect and the high rate of EPS and prolactin elevation.<\/p>\n

The MT (mouth-disintegrating \/ orodispersible) formulation dissolves on the tongue without water \u2014 useful in acutely psychotic patients with covert non-adherence and in dysphagia.<\/p>\n

Indica\u021bii \u0219i dozaj<\/h2>\n\n\n\n\n\n\n\n\n\n
Indica\u021bie<\/th>\nDoza ini\u021bial\u0103<\/th>\n\u021aint\u0103<\/th>\nMaxim<\/th>\n<\/tr>\n<\/thead>\n
Schizofrenie (adul\u021bi)<\/td>\n1\u20132 mg OD or BID<\/td>\n4\u20136 mg\/day<\/td>\n16 mg<\/td>\n<\/tr>\n
Schizofrenie (adolescent \u2265 13 ani)<\/td>\n0.5 mg OD<\/td>\n3 mg\/day<\/td>\n6 mg<\/td>\n<\/tr>\n
Bipolar mania<\/td>\n2\u20133 mg OD<\/td>\n2\u20136 mg\/day<\/td>\n6 mg<\/td>\n<\/tr>\n
Autism irritability (paediatric \u2265 5 y)<\/td>\n0.25\u20130.5 mg OD<\/td>\n0.5\u20133 mg\/day weight-based<\/td>\n2.5\u20133 mg<\/td>\n<\/tr>\n
Pacien\u021bi v\u00e2rstnici\/demen\u021b\u0103 (off-label, ultim\u0103 solu\u021bie)<\/td>\n0.25 mg OD<\/td>\n0.5\u20131 mg\/day<\/td>\n2 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Considera\u021bii importante de siguran\u021b\u0103<\/h2>\n
\nFDA black-box \u2014 psihoz\u0103 asociat\u0103 demen\u021bei<\/strong><\/p>\n

Toate antipsihoticele atipice poart\u0103 un avertisment FDA black-box pentru mortalitate crescut\u0103 (\u00een principal cardiovascular\u0103 \u0219i infec\u021bioas\u0103) atunci c\u00e2nd sunt utilizate pentru tratarea tulbur\u0103rilor de comportament la adul\u021bii \u00een v\u00e2rst\u0103 cu demen\u021b\u0103. Antipsihoticele atipice nu sunt aprobate pentru psihoza sau agita\u021bia asociat\u0103 demen\u021bei<\/strong>. Utilizarea \u00een aceast\u0103 popula\u021bie este off-label, de ultim\u0103 instan\u021b\u0103, limitat\u0103 \u00een timp \u0219i necesit\u0103 o discu\u021bie explicit\u0103 despre raportul risc-beneficiu.<\/p>\n<\/div>\n

\nHighest prolactin elevation of any atypical<\/strong><\/p>\n

Risperidone produces marked, dose-dependent hyperprolactinaemia. Clinical consequences:<\/strong> amenorrhoea, galactorrhoea, anovulation, and reduced bone density in women; loss of libido, erectile dysfunction, and gynaecomastia in men; in long-term use, accelerated osteoporosis. Check prolactin if symptoms suggest hyperprolactinaemia. If hyperprolactinaemia is symptomatic, consider switching to aripiprazole (lowers prolactin) or quetiapine.<\/p>\n<\/div>\n

\nEPS \/ dose-dependent<\/strong><\/p>\n

Above approximately 6 mg\/day, risperidone increasingly behaves like a typical antipsychotic on EPS \u2014 rigidity, tremor, akathisia, dystonia. Tardive dyskinesia risk is real but lower than typicals. Stay below 6 mg\/day where possible.<\/p>\n<\/div>\n

\nHipotensiune ortostatic\u0103<\/strong><\/p>\n

\u03b11 antagonism \u2014 common at initiation, particularly in older adults. Titrate slowly.<\/p>\n<\/div>\n

\nMetabolic burden<\/strong><\/p>\n

Less than olanzapine but real \u2014 weight gain typically 2\u20134 kg over 6 months. Monitor weight, fasting glucose, fasting lipids at baseline, 12 weeks, then 6-monthly.<\/p>\n<\/div>\n

Efecte secundare frecvente<\/h2>\n